Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia
James Devaney(National University of Ireland), John G. Laffey(University Hospital Galway)
Cited by 27
Related Papers
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies
|Intensive Care Medicine|2023|855
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|737